Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States

Hepatology

Volumn 65, Issue 4, 2017, Pages 1237-1248

  Cadier, Benjamin ^a,b   Bulsei, Julie ^a   Nahon, Pierre ^c,d,e   Seror, Olivier ^c,e   Laurent, Alexis ^a,g,h   Rosa, Isabelle ⁱ   Layese, Richard ^g,j   Costentin, Charlotte ^j   Cagnot, Carole ^f   Durand Zaleski, Isabelle ^a,b,j   Chevreul, Karine ^a,b,k  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Paris Diderot University   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e INSERM   (France)

^f Unit for Basic and Clinical research on Viral Hepatitis   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h INSERM U955   (France)

ⁱ CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL OUTCOME; COHORT ANALYSIS; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; EARLY CANCER DIAGNOSIS; ECONOMIC EVALUATION; FRANCE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MONITORING; RADIOFREQUENCY ABLATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; UNITED STATES; AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FACTUAL DATABASE; FEMALE; LIVER NEOPLASMS; MALE; MARKOV CHAIN; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COHORT STUDIES; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; FRANCE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES;

EID: 85012875221     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28961     Document Type: Article

References (49)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133–1145.
2. Binder-Foucard F, Bossard N, Delafosse P, Belot A, Woronoff AS, Remontet L. French network of cancer registries (Francim). Cancer incidence and mortality in France over the 1980-2012 period: solid tumors. Rev Epidemiol Sante Publique 2014;62:95–108.
3. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124–1130.
4. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, et al; ANRS CO12 CirVir group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2016 Sep 15. pii: S0016-5085(16)35070-3. doi: 10.1053/j.gastro.2016.09.009.
5. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98–107.
6. Mancebo A, González-Diéguez ML, Cadahía V, Varela M, Pérez R, Navascués CA, et al. Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clin Gastroenterol Hepatol 2013;11:95–101.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma : an update. Hepatology 2011;53:1020–1022.
8. National Health Authority guidance for the management of cirrhosis [in French]. September 2008. http://www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/doXiti.jsp?id=c_718956. Accessed December 19, 2016.
9. Hasset M, Yopp AC, Singal AG. Surveillance for hepatocellular carcinoma: how can we do better? Am J Med Sci 2013;346:308–313.
10. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861–867.
11. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkerts Prev 2012;21:793–799.
12. Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012;56:793–796.
13. Rosa I, Denis J, Renard P, Lesgourgues B, Dobri, AS, Becker C, et al.; CHANGH ANGH Study Group. French multicentric longitudinal descriptive study of hepatocellular carcinoma management, the CHANGH cohort: preliminary results. J Hepatol 2010;52:S231–S232.
14. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al.; Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987–1997.
15. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014;161:261–269.
16. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011;54:1998–2004.
17. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422–434.
18. Lim KC, Wang VW, Siddiqui FJ, Shi L, Chan ES, Oh HC, et al. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology 2015;61:227–237.
19. Qian MY, Yuwei JR, Angus P, Schelleman T, Johnson L, Gow P. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. J Gastroenterol Hepatol 2010;25:951–956.
20. Chang Y, Lairson DR, Chan W, Lu SN, Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. J Eval Clin Pract 2011;17:261–267.
21. Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Manag Healthc Policy 2012;5:49–54.
22. Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003;14:1463–1467.
23. HAS. Recommendations for health economic evaluation [in French]. October 2011. http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf. Accessed May 2016.
24. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231–250.
25. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, et al.; ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015;62:737–750.
26. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al.; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
27. HAS. Guidance for monitoring patients with uncomplicated cirrhosis and for the primary prevention of complications [in French]. September 2007. http://www.has-sante.fr/portail/upload/docs/application/pdf/surveillance_cirrhose_-_recommandations_2008_02_13__17_41_31_104.pdf.
28. Biomedicine Agency. Scientific activity report 2013. http://www.agence-biomedecine.fr/annexes/bilan2013/donnees/ldtf.htm. Accessed May 2016.
29. N'Kontchou G, Aout M, Laurent A, Nahon P, Ganne-Carrié N, Grando V, et al. Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis. J Hepatol 2012;56:160–166.
30. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med 1982;73:889–897.
31. http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/affection-de-longue-duree-ald/cout/cout-des-ald-en-2009.php. Accessed June 2015.
32. http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/, http://www.ameli.fr/accueil-de-la-ccam/index.php. Accessed June 2015.
33. National Health Information Agency. Tariffs and costs for hospital admissions [in French]. http://www.atih.sante.fr/tarifs-mco-et-had. Accessed December 2016.
34. Social security finance law, bylaw on hospital tariffs, 2015 [in French]. http://legifrance.gouv.fr/affichTexte.do;jsessionid=?cidTexte=JORFTEXT000030337500&dateTexte=&oldAction=dernierJO&categorieLien=id. Accessed June 2015.
35. Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population. JAMA Intern Med 2016;176:65–73.
36. Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186–1194.
37. Tapper EB, Sengupta N, Hunink MG, Afdhal NH, Lai M. Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography. Am J Gastroenterol 2015;110:1298–1304.
38. Andrieux V, Chantel C. Life expectancy and duration of retirement [in French]. Ministry of Health. DREES, no. 40 June 2013. http://drees.social-sante.gouv.fr/IMG/pdf/article40.pdf. Accessed December 2016.
39. Life expectancy tables [in French]. INSEE, 2012. [Online]. Available at: http://www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATnon02229. Accessed June 2015.
40. WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland: WHO; 2001.
41. http://donnees.banquemondiale.org/indicateur/NY.GDP.PCAP.CD. Accessed May 2016.
42. www.agence-biomedecine.fr/. Accessed September 2016.
43. Kuo MJ, Chen HH, Chen CL, Fann JC, Chen SL, Chiu SY, et al. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: comparing ultrasonography with two-stage screening. World J Gastroenterol 2016;22:3460–3470.
44. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004;19:1159–1172.
45. Canadian Agency for Drugs and Technologies in Health. Low-Dose Computed Tomography for Lung Cancer Screening: A Review of the Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines. Ottawa, Ontario, Canada: Canadian Agency for Drugs and Technologies in Health; 2015 Sep 22.
46. Wong CK, Lam CL, Wan YF, Fong DY. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing. BMC Cancer 2015;15:705.
47. Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, et al. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2014;107:366.
48. Noordzij MA, Blanker MH. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2015;107:djv110.
49. Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol 2013;27:961–972.